News & Events about Lexicon Pharmaceuticals Inc.
Data accepted as AAN Late-Breaking AbstractTHE WOODLANDS Texas, April 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that results from RELIEF-PHN-1, a Phase 2 double-blind, placebo-controlled trial of its investigational drug LX9211 for the treatment of ...
Ticker Report
2 months ago
StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX Get Rating) to a sell rating in a research report released on Saturday. Separately, Jefferies Financial Group started coverage on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 7th. They set a hold ...
Globe Newswire
3 months ago
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection fraction (LVEF) range THE WOODLANDS, Texas, March 04, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced new ...
Globe Newswire
3 months ago
Into the Dark
Into the Dark Campaign Image
Emphasizes challenges faced by patients and clinicians within the first 30 days after discharge from a heart failure hospitalization Reinforces impact of rehospitalizations for heart failure patients and healthcare system Campaign launches at American ...
Globe Newswire
3 months ago
Featured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failureTHE WOODLANDS, Texas, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF...